Bids Are Invited For Phsa 19229 Erythropoietin Stimulating Agents - Darbepoetin Alfa (Aranesp)

Phsa 19229 Erythropoietin Stimulating Agents - Darbepoetin Alfa (Aranesp) . Notice Of Intent To Direct Award Issued: July 17, 2026 File # Phsa 19229 Noi Title: Erythropoietin Stimulating Agents - Darbepoetin Alfa (Aranesp) Provincial Health Services Authority Notice Is Hereby Given That Provincial Health Services Authority (“Phsa”) Intends To Directly Award A Contract To The Following Supplier To Provide Erythropoietin Stimulating Agents - Darbepoietin Alfa (Aranesp) For A Term Of Five (5) Years At An Estimated Value Of $83.6M. Amgen Canada Inc 6775 Financial Drive, Suite 300 Mississauga, Ontario, Canada L5n 0A4 In Accordance With Applicable Trade Agreements, Phsa Has Chosen Not To Proceed With A Competitive Process For The Following Reason: • The Goods Or Services Can Be Supplied Only By The Selected Supplier And No Alternative Or Substitute Exists For The Following Reason: (A) Due To An Absence Of Competition For Technical Reasons. Currently, Erythropoietin Stimulating Agents (Esas) In British Columbia And Canada Are Supplied By Amgen Canada Inc. (Darbepoetin Alfa [Aranesp®]) And Janssen Inc. (Epoetin Alfa [Eprex®]). Janssen Inc. Has Announced The Discontinuation Of Eprex®, Effective April 30, 2027. As A Result, Aranesp® Will Become The Sole Esa Product Available In The Canadian Market, With No Biosimilar Alternatives Currently Approved In Canada. Vendors Who Wish To Challenge This Decision Should Submit A Detailed Written Objection For The Attention Of Pharmacy Sourcing Before 2:00Pm Pacific Time, July 27, 2026. Phsa Will Review Any And All Issues Received By This Date And Provide Due Consideration To Each Objection. Please Reference File: Phsa 19229 On All Written Correspondence.